Eisenmenger syndrome is associated with substantial morbidity and mortality. There is no consensus, however, on mortality risk stratification. We aimed to investigate survival and predictors of death in a large, contemporary cohort of Eisenmenger syndrome patients.
A dvances in surgical and percutaneous interventions in recent decades for patients with congenital heart disease (CHD) have improved survival prospects. Mortality, in comparison with the general population, however, remains higher for most lesions and patients require follow-up at tertiary CHD centers. 1 Eisenmenger syndrome (ES), defined as pulmonary arterial hypertension with a nonrestrictive intracardiac or extracardiac communication and chronic cyanosis, remains a major complication of shunt lesions. It may develop in patients who, for various reasons, did not undergo early surgery for CHD, but it may also occur in previously operated patients because of, for example, ineffective banding of pulmonary artery or residual shunt. When ES develops, repair of the underlying defect is contraindicated; patients thereafter are managed conservatively or occasionally referred for heart and lung transplantation. 2, 3 Patients with ES are severely limited in their physical capacity and are afflicted by significant morbidity and mortality. Only a proportion of ES patients makes it to adulthood. Because of the chronicity of the disease, the multiple adaptive mechanisms, and the subjectiveness of symptoms, the progression of disease is not fully appreciated, whereas mortality remains 13 times higher than in the general population. 1, 4 Last but not least, we are lacking reliable, multivariable mortality risk stratification tools in ES, which, in turn, limits our ability to identify high-risk patients. The aim of our study, therefore, was to identify predictors of death in a large cohort of patients with ES.
METHODS
We identified, from 11 dedicated adult CHD clinics (Royal Brompton Hospital, London, UK; Rigshospitalet, Copenhagen, Denmark; Anzhen Hospital, Beijing, China; Children's Hospital and Brigham and Women's Hospital, Boston, MA; University Hospitals Leuven, Belgium; Academic Medical Center, Amsterdam, Netherlands; Oslo University Hospital, Rikshosptalet, Oslo, Norway; Department of Cardiology, Lund University Hospital, Lund, Sweden; Jagiellonian University Medical College, Cracow, Poland; Second University of Naples, Italy; University Medical Center, Ljubljana, Slovenia) data on all adult patients (>16 years of age) with ES under active follow-up between 2000 and 2015. Ethical or research committee approval was obtained in each contributing center and all data were collected retrospectively. ES was defined as pulmonary arterial hypertension with a nonrestrictive intracardiac or extracardiac communication and chronic cyanosis. [5] [6] [7] The group with extracardiac communication included patients with severe pulmonary hypertension and reversed (right-to-left) shunt attributable to persistent ductus arteriosus, aortopulmonary windows, and large Waterston or Pott anastomosis. Diagnosis has been established and confirmed by echocardiography, cardiac MRI, and, in most cases, by cardiac catheterization. Baseline data were taken at the first assessment as an adult between 2000 and 2015, inclusive of clinical status, 12-lead ECG, transthoracic echocardiography, 6-minute walk test, and laboratory tests. Parameters were chosen for inclusion in data collection on the basis of a review of ES literature on single predictors of outcome. Patients were grouped by underlying shunt type into 3 categories: pretricuspid, posttricuspid, and complex. In the pretricuspid group, we included patients with large, nonrestrictive atrial septal defects and no significant posttricuspid lesions. The posttricuspid group included patients with large, nonrestrictive ventricular septal defects or patent ductus arteriosus and no major pretricuspid communications. The complex group included patients with both large pre-and posttricuspid defects.
Electrocardiographic parameters, including rhythm assessment, heart rate, and QRS duration, were collected manually from 12-lead ECGs. Arterial oxygen saturation was recorded using percutaneous pulse oximetry on the finger or, in patients with an isolated patent ductus arteriosus, on the toe. Sixminute walk test was performed according to the American Thoracic Society guidelines. 8 Oxygen saturation was recorded on air at rest and at peak exercise. Transthoracic echocardiography was performed by experienced operators. Presence of pericardial effusion was reported if the amount of fluid in the pericardial space was graded as abnormal by the investigator reviewing the study. Tricuspid annular plane systolic excursion (TAPSE) was recorded from the apical 4-chamber view on M mode in the lateral portion of the subpulmonary atrioventricular valve.
Albumin, brain natriuretic peptide, C-reactive protein, and sodium were the laboratory tests included. Normal ranges provided by centers were very similar for all these parameters and, thus, absolute values are presented, with the only
Clinical Perspective
What Is New?
• We performed a large, multicenter study in patients with Eisenmenger syndrome and we demonstrate contemporary management trends.
• At the end of the study, almost two-thirds of patients were on advanced therapy for pulmonary arterial hypertension, whereas 6 (0.55%) patients underwent lung or heart and lung transplantation.
• We demonstrate that, despite advances in management, there is significant mortality among contemporary adults with Eisenmenger syndrome, and 25.3% of patients died over a follow-up period of 3.1 years.
• On a multivariable model, mortality was higher in older patients and those with pretricuspid shunt, lower oxygen saturation, absence of sinus rhythm, or pericardial effusion.
What Are the Clinical Implications?
• We report a multivariable mortality risk stratification model based on 5 simple, noninvasive predictors of death in this population.
• These predictors identify a high-risk subgroup of patients with Eisenmenger syndrome.
exception of brain natriuretic peptide. For brain natriuretic peptide, the upper limits of normal varied between centers, and we present, therefore, the ratio of observed brain natriuretic peptide values to the provided, center-specific upper limits of normal. C-reactive protein was measured in patients without any obvious infection and without prior recent blood transfusion or surgery, as previously described. 9 Advanced therapy (AT) for pulmonary arterial hypertension, namely phosphodiesterase inhibitors, endothelin receptor antagonists, or prostanoids, was assessed as a time-dependent variable, as previously described. 10 Data on mortality were retrieved from national databases or patients' general practitioner records and were available in all patients.
Statistical Analysis
Data analysis was performed by using R-package for Windows, version 3.2.2.
11 Continuous data are shown as median and interquartile range. Comparison between 2 groups for continuous data was performed using the Wilcoxon rank sum test, whereas distribution for categorical data between groups was compared using the χ 2 test. All P values are 2-sided, and a P value of <0.05 was considered of statistical significance. Survival analysis was performed for all-cause mortality. We used right censoring for patients confirmed alive at the time of data collection or last contact and for patients undergoing heart and lung transplantation at the date of surgery. We calculated survival by using the Kaplan-Meier method; survival between groups was compared using the log-rank test. Association of single variables with survival was assessed using the univariable Cox proportional hazards method. Proportionality of hazards was confirmed in each case by assessing the correlation between the scaled Schoenfeld residuals and time. Univariable predictors with a P value of <0.1 were candidates for our multivariable Cox proportional hazards model. We included in this multivariable model only parameters with >80% data available. In an exploratory multivariable model, we also separately included parameters of particular clinical significance. A stepwise, backward method was used for selection of the multivariable Cox regression model. On univariable Cox regression, AT was analyzed as a time-dependent variable. On the multivariable Cox regression, we analyzed both a model with baseline data only, and, as sensitivity analysis, we analyzed AT as a time-dependent variable with baseline observation carried forward for the other parameters tested. The multivariable model was tested by clustering patients according to contributing adult CHD center. Correlation was assessed by using Spearman ρ.
RESULTS
In total, 1098 patients with ES fulfilled entry criteria and constituted our study population. Table 1 .001 for both comparisons). The majority of patients were female (65.1%); the percentage of females was highest in the pretricuspid group (81.0%). Almost one-third of patients presented with Down syndrome (n=350, 31.9%); most of them had a complex shunt (n=230, 66%) followed by posttricuspid defect (n=111, 32%), and only 9 had an isolated pretricuspid lesion. The median follow-up time was 3.1 years (1.-5.9), allowing for 4361.6 patient-years of observation time.
Functional Status, Six-Minute Walk Test, and Oxygen Saturation
Approximately half of the patients (51%) were in World Health Organization (WHO) functional class II, 47% were in class III, whereas 2% were in class IV (symptoms at rest). The median walking distance on the 6-minute walk test was 360 m (273-438); it was lower in patients with complex lesions (300 m 
Electrographic and Echocardiographic Data
The vast majority of patients (94.9%) were in sinus rhythm at baseline. Among the remainder, 59% were in atrial fibrillation or flutter, followed by 27% in paced rhythm, 7% in junctional, and 7% in atrial rhythm.
A pericardial effusion was identified in 9.2% of patients, in none of them described as hemodynamically compromising. Pericardial effusion was more common in patients with complex lesions (16.3%, P<0.001 
Advanced Therapy for Pulmonary Arterial Hypertension
Overall, 405 (36.9%) patients were on AT for pulmonary arterial hypertension at baseline. The proportion of patients on AT was lower among patients with Down syndrome (18.6% versus 45.5% in the remainder, P<0.001). Most patients (88.4%) were at baseline on monotherapy with endothelin receptor antagonist (41.7% of all treated patients), phosphodiesterase-5 inhibitor (38.8%) or a prostacyclin analog (prostaglandin I2 analog, 7.9%). Dual AT was used in 10.9% of patients (endothelin receptor antagonist and phosphodiesterase-5 inhibitor in 7.7%; phosphodiesterase-5 inhibitor and prostaglandin I2 analog in 2.7%; endothelin receptor antagonist and prostaglandin I2 analog in 0.5%). Only 0.7% of AT-treated patients were on a triple therapy. During the study, a further 324 (29.5%) patients were commenced on AT. Overall, AT was discontinued in 39 patients (5.7%); therefore, there were 690 (62.8%) patients on AT by the end of the study. there was no significant difference in survival between the posttricuspid and complex lesion groups ( Figure) . Table 2 presents the results of univariable Cox regression analysis for mortality. Overall, 12 parameters emerged as significant predictors of death, including age, type of shunt, WHO functional class >II, oxygen saturation at rest (but not oxygen saturation at peak exercise), presence of sinus rhythm, 6-minute walk distance, both presence of pericardial effusion and TAPSE, albumin, brain natriuretic peptide, C-reactive protein, and AT. The 6-minute walk distance was predictive of outcome on univariable analysis both in patients with and without Down syndrome (hazard ratio, 0.60 per 100 m; 95% CI, 0.41-0.88; P=0.009 and hazard ratio, 0.55 per 100 m; 95% CI, 0.44-0.68; P<0.001, respectively). On the basis of the preset criteria for parameter selection, the following parameters were tested in the multivariable model: age, WHO functional class, type of shunt, oxygen saturation at rest, presence of sinus rhythm, presence of pericardial effusion, and AT. Table 3 presents the 5 parameters that remained predictive of mortality in the multivariable model, namely age, presence of pretricuspid shunt, oxygen saturation at rest, presence of sinus rhythm, and presence of pericardial effusion. The same parameters remained in the model after stratification for WHO functional class and when analyzing for AT as a timedependent variable. This model remained stable also when clustering by contributing adult CHD center. In an exploratory multivariable analysis using a subset of patients with complete data, TAPSE did not contribute significantly to risk stratification (hazard ratio, 0.98/1 mm; 95% CI, 0.94-1.03; P=0.51); 6-minute walk test distance when added to other parameters remained in the model as a significant predictor of mortality (hazard ratio, 0.69/100 m; 95% CI, 0.56-0.85, P=0.001).
Survival and Predictors of Mortality

DISCUSSION
Our data show ongoing, significant mortality in a large, contemporary cohort of adults with ES. Survival prospects vary significantly for these patients depending on age, underlying shunt type, oxygen saturation at rest, presence of sinus rhythm, and presence of pericardial effusion. We present, herewith, a multivariable mortality risk stratification model based on these 5 simple, noninvasive parameters to assist with clinical care, optimization of therapy, and referral for transplantation.
ES is a truly multiorgan disease where multiple factors may contribute to premature death. 12 Thus, mortality risk prognostication must be based on a multivariable model. Age was clearly one of the most powerful determinants of mortality in our cohort. It has been suggested that mortality may be particularly high after the fourth decade of life. 13 Our data show, however, that, even in this older group of patients, survival prospects may be relatively sound, providing high resting oxygen saturation, presence of sinus rhythm, and absence of pericardial effusion. The level of shunting was also a strong determinant of outcome in our study as in previous studies. 14, 15 The majority of patients with an atrial septal defect tend to tolerate increased pulmonary blood flow well, do not develop pulmonary vascular disease, and, thus, are suitable for repair. 16 The minority of patients with pretricuspid shunt who develop ES seem to be afflicted both from the cardiac lesion and from predisposition, maybe genetic, to adverse pulmonary vascular remodeling with its negative impact on survival.
Furthermore, contrary to those with posttricuspid shunts, patients with pretricuspid shunts develop pressure load of the right ventricle late on in life. Thus, right ventricular adaptation fails or may be incomplete with resulting right ventricular dysfunction and failure. 17 Echocardiographic parameters were recently shown to convey prognostic information in ES. 18 However, there have been no agreed international protocols for echocardiography in ES to date, particularly for the assessment of the right ventricle. As a result, TAPSE, a marker of global longitudinal right ventricular function, although predictive of out- Figure. Survival by underlying shunt type.
Adjusted survival curves for patients with pretricuspid lesions (gray) and posttricuspid or complex shunt (black) with 95% confidence intervals. come in our univariable analysis, was not available in more than one-fifth of patients. In the exploratory multivariable model, TAPSE did not significantly contribute to mortality risk stratification, although these results are based on a restricted set of patients and should therefore be interpreted cautiously. Pericardial effusion, the echocardiographic parameter included in our multivariable prognostic model, was associated with more than a doubled risk of death. The reason for the presence of a pericardial effusion in a significant proportion of patients (9.2% overall, 15.8% in patients who died) and its high prognostic value remains unclear. As shown by Batal et al, 19 pericardial effu- sion is also common in patients with idiopathic pulmonary hypertension or pulmonary hypertension associated with connective tissue disease. In their study, however, pericardial effusion was associated with ventricular dysfunction in conjunction with right ventricular pressure and volume overload. In contrast, there was no association between TAPSE and pericardial effusion in our study. It is interesting to note that patients with pericardial effusion had significantly higher serum C-reactive protein levels, suggesting that an inflammatory component may have played a role, although patients had no clinical signs of active infection at the time of blood sampling.
Oxygen saturation was a predictor of outcome in ES in our study as in previous studies. 20, 21 Oxygen saturation reflects the extent of right-to-left shunting, but also the mixed venous saturation, which, in turn, relates to cardiac output and oxygen tissue delivery. Oxygen therapy improves oxygen saturation in ES patients. 22 Long-term oxygen therapy, however, does not seem to improve survival. 23 Chronic cyanosis in ES acts as a stimulator for secondary erythrocytosis, enhancing blood oxygencarrying capacity. 24 Six-minute walk distance, as in previous studies, was a significant predictor of outcome in our univariable analysis. 21 Moreover, in the exploratory multivariable analysis, it significantly contributed to mortality risk stratification, although these results are based on a restricted set of patients (57% of the study population) and should therefore be interpreted cautiously and considered exploratory in nature. Given the chronicity and rate of progression of ES, the prognostic significance of 6-minute walk distance is probably not surprising. In contrast to the study by Van De Bruaene et al, 20 6-minute walk test distance was also predictive of outcome in patients with Down syndrome. The majority of our patients were in WHO functional class II or III. As reported by Raphael et al, 25 there is a high interobserver variability in assessing functional class in chronic heart failure where the former does not correspond to objective measures of exercise capacity. This may also be the case in patients with ES, including patients with Down syndrome. Every effort should be made, therefore, for assessing exercise capacity formally with the 6-minute walk test in ES, rather than relying only on WHO functional class.
Our study has several potential limitations. It was conducted at tertiary adult CHD centers, and, thus, we cannot exclude referral bias; the majority of ES patients are under tertiary care however. The follow-up time was relatively short (median of 3.1 years). Clinical parameters change over time, however, particularly in deteriorating patients. 26, 27 If follow-up is long, these parameters need to be analyzed as time-dependent variables. This may complicate data collection and introduce bias because of missing data. The high number of patients (n=1098) and events (n=278) in the present study compensates further for the length of follow-up. Last but not least, our study was retrospective in nature. Future studies should validate our predictors of outcome in ES and shed light on risk stratification.
Our study has several important implications for the management of patients with ES. In our cohort, only 6 (0.55%) patients underwent heart and lung or lung-only transplantation, whereas 278 patients (25.3%) died. This disparity, in any case, reflects numerous challenges associated with transplantation in this population. Patients with ES, of course, may not be suitable for transplantation because of comorbidities, multiorgan involvement, presence of antibodies, or, occasionally, underlying cardiovascular anatomy that is too complex. Furthermore, mortality after heart and lung transplantation remains high, approaching 55% at 5 years, and data suggesting a mortality benefit for ES, in general, are lacking. 28 An important recent confounder has been the introduction of AT for pulmonary arterial hypertension with its established record of safety, efficacy in improving pulmonary hemodynamics, the 6-minute walk distance, 29 and functional class with a signal of survival benefit, albeit the latter in retrospective observational studies only. 10, 30 Treatment with AT was associated with improved survival in univariable analysis in the present, much larger study. This association was, however, lost in the multivariable analysis. The reason for this is probably multifactorial. A multicenter, double-blinded, randomized controlled study exploring the clinical impact of AT in ES, including survival, is warranted.
In conclusion, we report herewith 5 simple, noninvasive predictors of death in this population: namely age, underlying shunt type, oxygen saturation, presence of sinus rhythm, and presence of pericardial effusion. These predictors in a multivariable model identify a high-risk subgroup of ES patients.
